WHO bans hydroxychloroquine (HCQ) testing on COVID-19 patients
Geneva / New Delhi: The World Health Organization (WHO) has temporarily banned the testing of hydroxychloroquine (HCQ) on coronavirus patients. Director-General of the WHO, Dr. Tedros Adhanom Ghebreyesus, said on Monday that the decision was taken on the recommendation of an executive group, which conducted “Solidarity Trials” on the Covid-19 patients in 400 hospitals in 17 countries under the auspices of the WHO.
A report published last Friday in the leading health magazine, The Lancet, found that patients who were given the drug individually or with micronized antibiotics under a solidity trial had a higher mortality rate. Taking note of the report, the executive group has decided to study the effects of this drug more extensively and to stop using it now.
Mr. Tedros said that under the solidarity trial, 3,500 patients were being treated with four drugs or a combination of drugs. Only the HCQ test is temporarily suspended. The other three drugs or combination of drugs will continue to be used.
It is to be noted that HCQ drug is used in the treatment of malaria. It has been described by many countries, including the United States, as effective in the treatment of COVID-19. The United States also imported a large consignment of hydroxychloroquine (HCQ) from India. The government of India has put a ban on the export of the drug HCQ thought exported to the United States. The government of India had to face criticism from opposition parties for the same.